Listen on the go
CORRECT!
Next question
touchONCOLOGY touchONCOLOGY
    • FILTER YOUR SEARCH
    Content Type:
    Speciality:
    More Specialities
    Conference:
    More Conferences

    • Diagnostics and Screening

    An Introduction to Diagnostics and Screening

    Early detection of tumours is essential to increase the likelihood of complete remission. Screening strategies are not without risk; for example, mammography and prostate-specific antigen screening can lead to the detection of indolent lesions and subsequent overtreatment. Precision medicine has improved screening and diagnostic approaches; tumour-typing of breast tumours for oestrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 has informed treatment options. Many non-invasive diagnostic tools can be used directly at the point of care. It is hoped that advances in the genomic classification may lead to the identification of high-risk individuals in other types of cancer.

    Browse our selection of video highlights and short articles from the conference hub, which provide insights into the latest updates from major conferences, and a collection of peer-reviewed articles from the journal portfolio. These are complemented by a range of educational activities from our expert faculty, with patient outcomes at the forefront.

    Diagnostics and Screening Content

    Diagnostics and Screening
    Advancing precision medicine: ESMO updates tumour NGS guidelines 

    In line with the continuously expanding molecular landscape of cancer, the ESMO Precision Medicine Working Group (PMWG) has revised its recommendations for tumour next-generation sequencing (NGS).

    touchFEATURE
    The role of RNA-based next-generation sequencing in identifying pathogenic gene fusions
    For HCPs in: USA
    View Time: 15 mins Sponsored content

    A review of next-generation sequencing methods for identifying actionable gene fusions and improving outcomes in cancer patients.

     

    MAT-0085
    Date of Preparation: December 2023
    Diagnostics and Screening, Radiology, Radiotherapy
    Watch Time: 53 mins
    touchEXPERT OPINIONS
    Advancing the management of adult solid tumours in 2023, and beyond: Unlocking the potential of radiopharmaceuticals
    CE/CME ACCREDITED Dr Ana Kiess, Dr Stephen Graves, Dr Jason Starr, Prof. Jorge Garcia, Dr Erik Mittra

    Following a scientific primer, the role of radiopharmaceuticals in the management of neuroendocrine tumours and prostate cancer, alongside approaches to support clinical implementation, are explored by leading experts.

    Learning objectives
    Learning Objectives
    • Describe the underlying rationale and mechanism of action for radiopharmaceuticals in adult oncology
    • Recall the different types of radiopharmaceuticals (approved and in clinical development), and their specific properties
    • Summarize the latest efficacy and safety data available for radiopharmaceuticals in the management of adult solid tumours, including potential implications for current and future clinical practice
    • Propose strategies to support integration of radiopharmaceuticals into adult oncology pathways to individualize clinical management, and ultimately, optimize patient outcomes
    Haematology, Diagnostics and Screening
    Watch Time: 37 mins
    touchPANEL DISCUSSION
    Navigating pyruvate kinase deficiency today: How can the disease burden and unmet treatment needs be addressed?
    CE/CME ACCREDITED Dr Rachael Grace, Dr Hanny Al-Samkari, Dr Ami J Shah

    Three experts discuss the burden and clinical presentation of pyruvate kinase deficiency, as well as current and emerging therapeutic strategies.

    Learning objectives
    Learning Objectives
    • Recognize the signs and symptoms of PK deficiency and the burden of disease in affected patients
    • Evaluate established therapeutic strategies for PK deficiency and identify remaining unmet treatment needs
    • Describe novel and emerging therapeutic strategies for PK deficiency and how they may address current unmet needs
    Haematology, Diagnostics and Screening
    Watch Time: 37 mins
    touchMDT
    Facing clinical challenges associated with paroxysmal nocturnal haemoglobinuria
    Prof. Régis Peffault de Latour, Dr Will Evans, Ms Jess Ratcliffe

    Watch a leading haematologist, a primary care physician and a patient with paroxysmal nocturnal haemoglobinuria (PNH) share their perspectives on the clinical challenges associated with PNH.

    Learning objectives
    Learning Objectives
    • Summarize the signs and symptoms of PNH and how these inform the clinical diagnosis
    • Explain the benefits and limitations of current and emerging complement inhibitor therapies for PNH
    • Explain the burden of PNH and impact on patients’ quality of life
    Diagnostics and Screening
    Targets, Therapies and the Role of Serial Biopsies for Prognostication and Assessing Changes to Tumour Biology in Oesophageal and Oesophagogastric Junction Cancers
    Michael LaPelusa, Muhammad Hashim Hayat, Michael K Gibson

    touchREVIEWS in Oncology & Haematology. 2022;18(2):107-12 DOI: https://doi.org/10.17925/OHR.2022.18.2.107

    Cancers of the oesophagus and oesophagogastric junction (OGJ), termed upper gastrointestinal (UGI) cancers, are lethal and constitute a significant public health problem. In 2020, 604,000 cases and 544,000 UGI cancer-related deaths were estimated worldwide.1 UGI cancers are the seventh most frequently diagnosed cancer and the sixth most common cause of cancer-related death.1 In the USA, there were […]

    Endocrine Cancers, Diagnostics and Screening
    Watch Time: 45 mins
    touchMDT
    Advancing the multidisciplinary management of rare and unusual NETs: Integrating new approaches to treatment and care
    CE/CME ACCREDITED Dr Diane Reidy-Lagunes, Prof. Dr med. Marianne Pavel, Dr Thomas Hope, Catherine Bouvier Ellis

    Watch leading specialists involved in the multidisciplinary care of patients with rare and unusual neuroendocrine tumours discuss new and emerging approaches for diagnosis and treatment.

    Learning objectives
    Learning Objectives
    • Recognize the role of the MDT in addressing diagnostic and treatment challenges associated with rare and unusual neuroendocrine tumours (NETs)
    • Evaluate the factors guiding treatment selection and clinical management decisions in rare and unusual NETs
    • Appraise the efficacy and safety of new and emerging treatment options for rare and unusual NETs
    Diagnostics and Screening, Head and Neck Cancer, Supportive Cancer Care
    Watch Time: 49 mins
    touchMDT
    Implementing a personalized approach to treatment of thyroid cancer: the importance of biomarker testing and targeted therapies
    CE/CME ACCREDITED Dr Lori Wirth, Dr Peter Sadow, Dr Antonio Matrone, Ms Tara Hurley Translations available:

    Watch leading specialists within an MDT discuss the importance of biomarker testing and targeted therapies for personalizing management of thyroid cancer

    Learning objectives
    Learning Objectives
    • Distinguish between different types of thyroid cancers and identify appropriate therapies for their management
    • Plan for the use of precision medicine in thyroid cancer, including implementation of biomarker testing and use of novel targeted therapies
    • Evaluate the clinical trial data for novel targeted therapies for thyroid cancer and translate it into clinical practice
    Diagnostics and Screening
    Criteria for Evaluating Multi-cancer Early Detection Tests
    Glenn D Braunstein, Joshua J Ofman

    touchREVIEWS in Oncology & Haematology. 2021;17(1):3-6 DOI: https://doi.org/10.17925/OHR.2021.17.1.3

    Somatic DNA mutational analysis has transformed how we characterize existing cancer and select treatments. For example, circulating tumour cell-free DNA (cfDNA) can be used to select targeted therapies, monitor treatment response and detect disease recurrence.1 However, early attempts with targeted sequencing of circulating tumour cfDNA to screen for multiple cancers were unsuccessful because of low sensitivity […]

    In Partnership with...
    Useful Links:
    About us Society Partners Press Releases Contact Us Permissions Terms & Conditions Privacy Policy Cookie Preferences
    Connect With Us:

    Other websites from Touch Medical Media:

    touchONCOLOGY
    touchOPHTHALMOLOGY
    touchENDOCRINOLOGY
    touchNEUROLOGY
    touchCARDIO
    touchRESPIRATORY
    touchIMMUNOLOGY
    touchINFECTIOUS DISEASES
    touchHAEMATOLOGY
    touchDERMATOLOGY

    Copyright® 2024 Touch Medical Media. Touch Medical Media Group Holdings Limited, a private limited company registered in England and Wales at 3 Stockport Exchange | Stockport | Cheshire | SK1 3GG | UK with registered number 08197142.

    touchONCOLOGY is for informational purposes and intended for healthcare professionals only. Its content should not be considered medical advice, diagnosis or treatment recommendations.

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
    Close Popup